☆ 4.7 Article

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial

LANCET NEUROLOGY (2021)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy

Deepa Chand et al.

Summary: This study focuses on the risk of liver injury associated with OA in the treatment of SMA and provides guidance on its management. Analysis of data from 325 patients receiving OA treatment showed elevated liver function test results in some patients. Most patients mitigated these adverse effects through prophylactic prednisolone treatment.

JOURNAL OF HEPATOLOGY (2021)

Add to Collection

Article Pediatrics

Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series

Deepa H. Chand et al.

Summary: Spinal muscular atrophy is treated with onasemnogene abeparvovec, but it can lead to drug-induced thrombotic microangiopathy in some infants. Early recognition and treatment of this complication may reduce mortality and morbidity.

JOURNAL OF PEDIATRICS (2021)

Add to Collection

Article Clinical Neurology

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial

John W. Day et al.

Summary: The study evaluated the safety and efficacy of onasemnogene abeparvovec gene therapy in symptomatic patients with infantile-onset spinal muscular atrophy. Results showed that patients achieved independent sitting and survival rates without permanent ventilation at certain time points, with a favorable benefit-risk profile supporting the use of onasemnogene abeparvovec for treatment of this condition.

LANCET NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy

Jerry R. Mendell et al.

Summary: This ongoing study evaluates the long-term safety and effectiveness of onasemnogene abeparvovec gene replacement therapy in infants with SMA type 1. The therapeutic dose showed sustained clinical benefits for patients with no need for permanent ventilation up to 6 years of age.

JAMA NEUROLOGY (2021)

Add to Collection

Review Genetics & Heredity

Longitudinal natural history of type I spinal muscular atrophy: a critical review

Eugenio Mercuri et al.

ORPHANET JOURNAL OF RARE DISEASES (2020)

Add to Collection

Article Clinical Neurology

AVXS-101 (Onasemnogene Abeparvovec) for SMA 1: Comparative Study with a Prospective Natural History Cohort

Samiah A. Al-Zaidy et al.

JOURNAL OF NEUROMUSCULAR DISEASES (2019)

Add to Collection

Article Medicine, General & Internal

Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy

J. R. Mendell et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Clinical Neurology

Natural history of infantile-onset spinal muscular atrophy

Stephen J. Kolb et al.

ANNALS OF NEUROLOGY (2017)

Add to Collection

Article Clinical Neurology

Developmental milestones in type I spinal muscular atrophy

Roberto De Sanctis et al.

NEUROMUSCULAR DISORDERS (2016)

Add to Collection

Article Clinical Neurology

Observational study of spinal muscular atrophy type I and implications for clinical trials

Richard S. Finkel et al.

NEUROLOGY (2014)

Add to Collection

Article Pediatrics

Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)

Allan M. Glanzman et al.

PEDIATRIC PHYSICAL THERAPY (2011)

Add to Collection

Article Clinical Neurology

The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): Test development and reliability

A. M. Glanzman et al.

NEUROMUSCULAR DISORDERS (2010)

Add to Collection

Article Genetics & Heredity

Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2

MD Mailman et al.

GENETICS IN MEDICINE (2002)

Add to Collection

Article Biochemistry & Molecular Biology

Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis

DM McCarty et al.

GENE THERAPY (2001)

Add to Collection

Article Biotechnology & Applied Microbiology

CMV-β-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1α promoter and results in therapeutic levels of human factor X in mice

LF Xu et al.

HUMAN GENE THERAPY (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.